PolyPeptide Group AG, a specialized global contract development and manufacturing organization for peptide-based active pharmaceutical ingredients, announced that its shareholders approved all proposals put forward by the board of directors at an extraordinary general meeting held on October 26, 2026. The approvals mark a significant step toward the completion of a public tender offer by Samsung Peptide AG, a wholly owned subsidiary of Samsung Biologics Co., Ltd., for all publicly held registered shares of PolyPeptide.
According to the announcement, shareholders elected John Chongbo Rim, Seungho Ryu, Cheol Woo Ryu, Mihyun Yang and Joonkyung Seong as members of the board for a term ending at the conclusion of the next annual general meeting. John Chongbo Rim was elected as chair of the board, while Cheol Woo Ryu and Seungho Ryu were elected as members of the Remuneration and Nomination Committee. All elections are subject to and effective as of the settlement of the Samsung Peptide AG tender offer.
In addition, shareholders resolved to remove the transfer restrictions and voting limitations from PolyPeptide’s articles of association, subject to the satisfaction or waiver of all offer conditions set forth in the offer prospectus of Samsung Peptide AG dated August 31, 2026, with the exception of the offer condition in section B.7.1(e). The removal of these restrictions is a critical condition for the tender offer, as it eliminates barriers to the acquisition of shares and the exercise of voting rights by the acquirer.
The board overhaul and the elimination of transfer restrictions are pivotal for the takeover. The new board, which includes nominees linked to Samsung Biologics, will be positioned to oversee the company’s integration once the offer settles. The changes also simplify the share structure, potentially accelerating the completion of the transaction. PolyPeptide, which dates back to 1952 and operates six GMP-certified facilities across Europe, the U.S. and India, serves a fast-growing market for peptide-based therapies, including significant exposure to metabolic diseases such as GLP-1. The company’s shares are listed on SIX Swiss Exchange under the ticker PPGN.
The extraordinary general meeting’s outcomes were reported by NEWMEDIAWIRE. For further details on PolyPeptide, visit polypeptide.com, and follow the company on LinkedIn. The full release is available at www.newmediawire.com.
